Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cyclophosphamide offers superior GVHD prophylaxis

Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.

Key clinical point: A cyclophosphamide-containing posttransplant regimen bested controls for reducing graft versus host disease rates.

Major finding: The hazard ratio for GVHD-free and relapse-free survival was 0.72 for those receiving cyclophosphamide, compared with controls (P = .04).

Study details: Randomized, controlled trial of 497 patients receiving one of three intervention arm posttransplant regimens for GVHD prophylaxis, or a control regimen of tacrolimus and methotrexate.

Disclosures: Dr. Bolaños-Meade reported serving on the data safety monitoring board of Incyte.

Source: Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.

Read the article.

Citation:

Bolaños-Meade J et al. 2018 BMT Tandem Meetings, Abstract LB1.

This Week's Must Reads

Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30

Phase 2 trial evaluates entospletinib in DLBCL, Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331

Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Must Reads in Cellular Therapy

CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

auto-FMT could help ease GVHD after transplant, Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489

Blood type is diarrhea destiny, Kumar P et al. J Clin Invest. 2018 May 17; doi: 10.1172/JCI97659.

Fertility poor irrespective of conditioning regimen for transplants , Oquendo del Toro H et al. The 2018 Bone Marrow Transplant Tandem Meetings, Abstract 88.